Interestingly, we found that hypomethylation of MXD3 was positively associated with dysfunctional T cell phenotypes (Fig. 5B) and shorter survival durations of the brain, melanoma, metastatic melanoma, leukemia, breast cancer, and KIRC cohorts. Here, MXD3 is linked to breast cancer.